Clinical Trial Update: Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia [Phase 2]

View source ↗

Summary

Phase II study of denileukin diftitox (Ontak) in adult T-cell leukemia was terminated; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• T-cell Leukemia

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Adult T-Cell | Phase 2 | Status: TERMINATED | Results posted: 2012-10-25